



ATP: ACTC's Platform Trial Testing New Tau Therapies in Alzheimer's Disease

Launching Summer 2026 | Approximately 78 U.S. Sites | Evaluating Novel Tau-Targeted Therapies

The Alzheimer's Tau Platform (ATP) is an NIH funded core platform trial of the Alzheimer's Clinical Trials Consortium (ACTC). **The ATP Study is designed to accelerate testing of promising investigational therapies that target tau, a key driver of Alzheimer's disease.**

ATP is among the first trials to test combination approaches of anti-amyloid and anti-tau treatments, which may provide greater benefit than testing amyloid- lowering treatment alone.

Why Tau?

Tau accumulation is closely linked to memory and thinking changes in Alzheimer's disease, making it an important target for new treatments.

Why Platform Trials?

Platform trials allow multiple therapies to be tested within a shared study structure, helping researchers evaluate promising treatments more efficiently.

Why ACTC?

ACTC provides the clinical trial infrastructure and expertise needed to efficiently conduct complex platform trials in the earliest stages of Alzheimer's disease.



The ACTC network is **advancing** the development of treatments for Alzheimer's disease and related disorders.



STUDY LAUNCH:

Summer 2026



PLATFORM STUDY DESIGN:

Participants will randomly be assigned to one of three intervention arms within a regimen.

Regimen 1:

Arm 1. Placebo followed by the tau vaccine AADvac1 Arm 2.

Donanemab® followed by the tau vaccine AADvac1

Arm 3. Donanemab® followed by a placebo

Regimen 2: Pending



TOTAL ENROLLMENT:

Up to 825 participants.



STUDY SITES:

~78 study sites across the U.S.




PARTICIPATION LENGTH:

~30 months (2.5 years)

The ATP study is led by researchers from the University of California, San Francisco and Mass General Brigham and is conducted through the Alzheimer's Clinical Trials Consortium (ACTC), a nationwide network of Alzheimer's disease clinical trial sites. Funding is provided by the National Institute on Aging, part of the National Institutes of Health.



actcinfo.org



Interested in ATP?

Scan to learn more about the study:
actcinfo.org/trials

General Eligibility Requirements*

- Between 50 to 80 years old
- Have no symptoms or mild symptoms of Alzheimer's disease
- Have no prior treatment with amyloid- or tau-directed therapy
- Have a study partner (such as a family member or friend)
- Be willing to complete all study procedures such as blood tests and brain imaging
- Blood tests and/or amyloid or tau PET scans show signs of amyloid or tau

**Further screening at a local site will help determine qualification*